<Metabolites><creation_date>2005-11-16 15:48:42 UTC</creation_date><update_date>10:17:17</update_date><version>4</version><name>Biotin</name><accession>HMDB0000030</accession><completion_status>In progress</completion_status><ranges><range><sex>Both</sex><age><min_age>0</min_age><max_age>64</max_age></age><ethnicity>NA</ethnicity><unit>Um</unit><min_range>0.0006000000000000001</min_range><max_range>0.13</max_range><diseases><disease>Acute Lymphoblastic Leukemia<references><reference><reference_text>Bogusiewicz A, Stratton SL, Ellison DA, Mock DM: Biotin accounts for less than half of all biotin and biotin metabolites in the cerebrospinal fluid of children. Am J Clin Nutr. 2008 Nov;88(5):1291-6.</reference_text><pubmed_id>18996865</pubmed_id></reference></references></disease><disease>Dementia<references><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Redjems-Bennani N, Jeandel C, Lefebvre E, Blain H, Vidailhet M, Gueant JL: Abnormal substrate levels that depend upon mitochondrial function in cerebrospinal fluid from Alzheimer patients. Gerontology. 1998;44(5):300-4.</reference_text><pubmed_id>9693263</pubmed_id></reference><reference><reference_text>Jeitner TM, Bogdanov MB, Matson WR, Daikhin Y, Yudkoff M, Folk JE, Steinman L, Browne SE, Beal MF, Blass JP, Cooper AJ: N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. J Neurochem. 2001 Dec;79(5):1109-12.</reference_text><pubmed_id>11739625</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference></references></disease><disease>Epilepsy<references><reference><reference_text>Rainesalo S, Keranen T, Palmio J, Peltola J, Oja SS, Saransaari P: Plasma and cerebrospinal fluid amino acids in epileptic patients. Neurochem Res. 2004 Jan;29(1):319-24.</reference_text><pubmed_id>14992292</pubmed_id></reference><reference><reference_text>Cady EB, Lorek A, Penrice J, Reynolds EO, Iles RA, Burns SP, Coutts GA, Cowan FM: Detection of propan-1,2-diol in neonatal brain by in vivo proton magnetic resonance spectroscopy. Magn Reson Med. 1994 Dec;32(6):764-7.</reference_text><pubmed_id>7869898</pubmed_id></reference><reference><reference_text>Perosa SR, Porcionatto MA, Cukiert A, Martins JR, Amado D, Nader HB, Cavalheiro EA, Leite JP, Naffah-Mazzacoratti MG: Extracellular matrix components are altered in the hippocampus, cortex, and cerebrospinal fluid of patients with mesial temporal lobe epilepsy. Epilepsia. 2002;43 Suppl 5:159-61.</reference_text><pubmed_id>12121313</pubmed_id></reference><reference><reference_text>Spanaki MV, Siegel H, Kopylev L, Fazilat S, Dean A, Liow K, Ben-Menachem E, Gaillard WD, Theodore WH: The effect of vigabatrin (gamma-vinyl GABA) on cerebral blood flow and metabolism. Neurology. 1999 Oct 22;53(7):1518-22.</reference_text><pubmed_id>10534261</pubmed_id></reference><reference><reference_text>Rating D, Siemes H, Loscher W: Low CSF GABA concentration in children with febrile convulsions, untreated epilepsy, and meningitis. J Neurol. 1983;230(4):217-25.</reference_text><pubmed_id>6198481</pubmed_id></reference><reference><reference_text>Botez MI, Young SN: Effects of anticonvulsant treatment and low levels of folate and thiamine on amine metabolites in cerebrospinal fluid. Brain. 1991 Feb;114 ( Pt 1A):333-48.</reference_text><pubmed_id>1705463</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Czarnecka J, Cieslak M, Michal K: Application of solid phase extraction and high-performance liquid chromatography to qualitative and quantitative analysis of nucleotides and nucleosides in human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Aug 5;822(1-2):85-90.</reference_text><pubmed_id>15993662</pubmed_id></reference><reference><reference_text>Shaywitz BA, Cohen DJ, Bowers MB: Reduced cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in children with epilepsy. Neurology. 1975 Jan;25(1):72-9.</reference_text><pubmed_id>803305</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Romigi A, Bari M, Placidi F, Marciani MG, Malaponti M, Torelli F, Izzi F, Prosperetti C, Zannino S, Corte F, Chiaramonte C, Maccarrone M: Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy. Epilepsia. 2010 May;51(5):768-72. doi: 10.1111/j.1528-1167.2009.02334.x. Epub 2009 Oct 8.</reference_text><pubmed_id>19817812</pubmed_id></reference><reference><reference_text>Hirai K, Seki T: Cerebrospinal fluid somatostatin levels in febrile seizures and epilepsy in children. Neuropeptides. 2000 Feb;34(1):18-24.</reference_text><pubmed_id>10688964</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference></references></disease><disease>Head injury<references><reference><reference_text>Lambert G, Naredi S, Eden E, Rydenhag B, Friberg P: Monoamine metabolism and sympathetic nervous activation following subarachnoid haemorrhage: influence of gender and hydrocephalus. Brain Res Bull. 2002 May;58(1):77-82.</reference_text><pubmed_id>12121816</pubmed_id></reference><reference><reference_text>Bogusiewicz A, Stratton SL, Ellison DA, Mock DM: Biotin accounts for less than half of all biotin and biotin metabolites in the cerebrospinal fluid of children. Am J Clin Nutr. 2008 Nov;88(5):1291-6.</reference_text><pubmed_id>18996865</pubmed_id></reference><reference><reference_text>Sachse KT, Jackson EK, Wisniewski SR, Gillespie DG, Puccio AM, Clark RS, Dixon CE, Kochanek PM: Increases in cerebrospinal fluid caffeine concentration are associated with favorable outcome after severe traumatic brain injury in humans. J Cereb Blood Flow Metab. 2008 Feb;28(2):395-401. Epub 2007 Aug 8.</reference_text><pubmed_id>17684518</pubmed_id></reference><reference><reference_text>Darwish RS, Amiridze N, Aarabi B: Nitrotyrosine as an oxidative stress marker: evidence for involvement in neurologic outcome in human traumatic brain injury. J Trauma. 2007 Aug;63(2):439-42.</reference_text><pubmed_id>17693848</pubmed_id></reference><reference><reference_text>Bayir H, Kochanek PM, Liu SX, Arroyo A, Osipov A, Jiang J, Wisniewski S, Adelson PD, Graham SH, Kagan VE: Increased S-nitrosothiols and S-nitrosoalbumin in cerebrospinal fluid after severe traumatic brain injury in infants and children: indirect association with intracranial pressure. J Cereb Blood Flow Metab. 2003 Jan;23(1):51-61.</reference_text><pubmed_id>12500091</pubmed_id></reference><reference><reference_text>Burke EJ, Mehlhorn U, Allen SJ: Hyaluronan in cerebrospinal fluid after head injury. Acta Neurol (Napoli). 1994 Jun;16(3):103-9.</reference_text><pubmed_id>7992658</pubmed_id></reference></references></disease><disease>Motor neuron disease<references><reference><reference_text>Shukla R, Rajani M, Barthwal MK, Srivastava N, Dikshit M: Cerebrospinal fluid nitrite and malondialdehyde levels in patients with motor neuron disease. Int J Neurosci. 2003 Aug;113(8):1043-54.</reference_text><pubmed_id>12888419</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Seckl JR, Lightman SL, Guiloff RJ: Elevated cerebrospinal fluid vasopressin in motor neuron disease. J Neurol Neurosurg Psychiatry. 1987 Jun;50(6):795-7.</reference_text><pubmed_id>3612158</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Eosinophilic esophagitis<references><reference><reference_text>Mordechai, Hien, and David S. Wishart</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Acute Lymphoblastic Leukemia<references><reference><reference_text>Bogusiewicz A, Stratton SL, Ellison DA, Mock DM: Biotin accounts for less than half of all biotin and biotin metabolites in the cerebrospinal fluid of children. Am J Clin Nutr. 2008 Nov;88(5):1291-6.</reference_text><pubmed_id>18996865</pubmed_id></reference></references></disease><disease>Dementia<references><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Redjems-Bennani N, Jeandel C, Lefebvre E, Blain H, Vidailhet M, Gueant JL: Abnormal substrate levels that depend upon mitochondrial function in cerebrospinal fluid from Alzheimer patients. Gerontology. 1998;44(5):300-4.</reference_text><pubmed_id>9693263</pubmed_id></reference><reference><reference_text>Jeitner TM, Bogdanov MB, Matson WR, Daikhin Y, Yudkoff M, Folk JE, Steinman L, Browne SE, Beal MF, Blass JP, Cooper AJ: N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. J Neurochem. 2001 Dec;79(5):1109-12.</reference_text><pubmed_id>11739625</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference></references></disease><disease>Epilepsy<references><reference><reference_text>Rainesalo S, Keranen T, Palmio J, Peltola J, Oja SS, Saransaari P: Plasma and cerebrospinal fluid amino acids in epileptic patients. Neurochem Res. 2004 Jan;29(1):319-24.</reference_text><pubmed_id>14992292</pubmed_id></reference><reference><reference_text>Cady EB, Lorek A, Penrice J, Reynolds EO, Iles RA, Burns SP, Coutts GA, Cowan FM: Detection of propan-1,2-diol in neonatal brain by in vivo proton magnetic resonance spectroscopy. Magn Reson Med. 1994 Dec;32(6):764-7.</reference_text><pubmed_id>7869898</pubmed_id></reference><reference><reference_text>Perosa SR, Porcionatto MA, Cukiert A, Martins JR, Amado D, Nader HB, Cavalheiro EA, Leite JP, Naffah-Mazzacoratti MG: Extracellular matrix components are altered in the hippocampus, cortex, and cerebrospinal fluid of patients with mesial temporal lobe epilepsy. Epilepsia. 2002;43 Suppl 5:159-61.</reference_text><pubmed_id>12121313</pubmed_id></reference><reference><reference_text>Spanaki MV, Siegel H, Kopylev L, Fazilat S, Dean A, Liow K, Ben-Menachem E, Gaillard WD, Theodore WH: The effect of vigabatrin (gamma-vinyl GABA) on cerebral blood flow and metabolism. Neurology. 1999 Oct 22;53(7):1518-22.</reference_text><pubmed_id>10534261</pubmed_id></reference><reference><reference_text>Rating D, Siemes H, Loscher W: Low CSF GABA concentration in children with febrile convulsions, untreated epilepsy, and meningitis. J Neurol. 1983;230(4):217-25.</reference_text><pubmed_id>6198481</pubmed_id></reference><reference><reference_text>Botez MI, Young SN: Effects of anticonvulsant treatment and low levels of folate and thiamine on amine metabolites in cerebrospinal fluid. Brain. 1991 Feb;114 ( Pt 1A):333-48.</reference_text><pubmed_id>1705463</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Czarnecka J, Cieslak M, Michal K: Application of solid phase extraction and high-performance liquid chromatography to qualitative and quantitative analysis of nucleotides and nucleosides in human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Aug 5;822(1-2):85-90.</reference_text><pubmed_id>15993662</pubmed_id></reference><reference><reference_text>Shaywitz BA, Cohen DJ, Bowers MB: Reduced cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in children with epilepsy. Neurology. 1975 Jan;25(1):72-9.</reference_text><pubmed_id>803305</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Romigi A, Bari M, Placidi F, Marciani MG, Malaponti M, Torelli F, Izzi F, Prosperetti C, Zannino S, Corte F, Chiaramonte C, Maccarrone M: Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy. Epilepsia. 2010 May;51(5):768-72. doi: 10.1111/j.1528-1167.2009.02334.x. Epub 2009 Oct 8.</reference_text><pubmed_id>19817812</pubmed_id></reference><reference><reference_text>Hirai K, Seki T: Cerebrospinal fluid somatostatin levels in febrile seizures and epilepsy in children. Neuropeptides. 2000 Feb;34(1):18-24.</reference_text><pubmed_id>10688964</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference></references></disease><disease>Head injury<references><reference><reference_text>Lambert G, Naredi S, Eden E, Rydenhag B, Friberg P: Monoamine metabolism and sympathetic nervous activation following subarachnoid haemorrhage: influence of gender and hydrocephalus. Brain Res Bull. 2002 May;58(1):77-82.</reference_text><pubmed_id>12121816</pubmed_id></reference><reference><reference_text>Bogusiewicz A, Stratton SL, Ellison DA, Mock DM: Biotin accounts for less than half of all biotin and biotin metabolites in the cerebrospinal fluid of children. Am J Clin Nutr. 2008 Nov;88(5):1291-6.</reference_text><pubmed_id>18996865</pubmed_id></reference><reference><reference_text>Sachse KT, Jackson EK, Wisniewski SR, Gillespie DG, Puccio AM, Clark RS, Dixon CE, Kochanek PM: Increases in cerebrospinal fluid caffeine concentration are associated with favorable outcome after severe traumatic brain injury in humans. J Cereb Blood Flow Metab. 2008 Feb;28(2):395-401. Epub 2007 Aug 8.</reference_text><pubmed_id>17684518</pubmed_id></reference><reference><reference_text>Darwish RS, Amiridze N, Aarabi B: Nitrotyrosine as an oxidative stress marker: evidence for involvement in neurologic outcome in human traumatic brain injury. J Trauma. 2007 Aug;63(2):439-42.</reference_text><pubmed_id>17693848</pubmed_id></reference><reference><reference_text>Bayir H, Kochanek PM, Liu SX, Arroyo A, Osipov A, Jiang J, Wisniewski S, Adelson PD, Graham SH, Kagan VE: Increased S-nitrosothiols and S-nitrosoalbumin in cerebrospinal fluid after severe traumatic brain injury in infants and children: indirect association with intracranial pressure. J Cereb Blood Flow Metab. 2003 Jan;23(1):51-61.</reference_text><pubmed_id>12500091</pubmed_id></reference><reference><reference_text>Burke EJ, Mehlhorn U, Allen SJ: Hyaluronan in cerebrospinal fluid after head injury. Acta Neurol (Napoli). 1994 Jun;16(3):103-9.</reference_text><pubmed_id>7992658</pubmed_id></reference></references></disease><disease>Motor neuron disease<references><reference><reference_text>Shukla R, Rajani M, Barthwal MK, Srivastava N, Dikshit M: Cerebrospinal fluid nitrite and malondialdehyde levels in patients with motor neuron disease. Int J Neurosci. 2003 Aug;113(8):1043-54.</reference_text><pubmed_id>12888419</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Seckl JR, Lightman SL, Guiloff RJ: Elevated cerebrospinal fluid vasopressin in motor neuron disease. J Neurol Neurosurg Psychiatry. 1987 Jun;50(6):795-7.</reference_text><pubmed_id>3612158</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Eosinophilic esophagitis<references><reference><reference_text>Mordechai, Hien, and David S. Wishart</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Acute Lymphoblastic Leukemia<references><reference><reference_text>Bogusiewicz A, Stratton SL, Ellison DA, Mock DM: Biotin accounts for less than half of all biotin and biotin metabolites in the cerebrospinal fluid of children. Am J Clin Nutr. 2008 Nov;88(5):1291-6.</reference_text><pubmed_id>18996865</pubmed_id></reference></references></disease><disease>Dementia<references><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Redjems-Bennani N, Jeandel C, Lefebvre E, Blain H, Vidailhet M, Gueant JL: Abnormal substrate levels that depend upon mitochondrial function in cerebrospinal fluid from Alzheimer patients. Gerontology. 1998;44(5):300-4.</reference_text><pubmed_id>9693263</pubmed_id></reference><reference><reference_text>Jeitner TM, Bogdanov MB, Matson WR, Daikhin Y, Yudkoff M, Folk JE, Steinman L, Browne SE, Beal MF, Blass JP, Cooper AJ: N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. J Neurochem. 2001 Dec;79(5):1109-12.</reference_text><pubmed_id>11739625</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference></references></disease><disease>Epilepsy<references><reference><reference_text>Rainesalo S, Keranen T, Palmio J, Peltola J, Oja SS, Saransaari P: Plasma and cerebrospinal fluid amino acids in epileptic patients. Neurochem Res. 2004 Jan;29(1):319-24.</reference_text><pubmed_id>14992292</pubmed_id></reference><reference><reference_text>Cady EB, Lorek A, Penrice J, Reynolds EO, Iles RA, Burns SP, Coutts GA, Cowan FM: Detection of propan-1,2-diol in neonatal brain by in vivo proton magnetic resonance spectroscopy. Magn Reson Med. 1994 Dec;32(6):764-7.</reference_text><pubmed_id>7869898</pubmed_id></reference><reference><reference_text>Perosa SR, Porcionatto MA, Cukiert A, Martins JR, Amado D, Nader HB, Cavalheiro EA, Leite JP, Naffah-Mazzacoratti MG: Extracellular matrix components are altered in the hippocampus, cortex, and cerebrospinal fluid of patients with mesial temporal lobe epilepsy. Epilepsia. 2002;43 Suppl 5:159-61.</reference_text><pubmed_id>12121313</pubmed_id></reference><reference><reference_text>Spanaki MV, Siegel H, Kopylev L, Fazilat S, Dean A, Liow K, Ben-Menachem E, Gaillard WD, Theodore WH: The effect of vigabatrin (gamma-vinyl GABA) on cerebral blood flow and metabolism. Neurology. 1999 Oct 22;53(7):1518-22.</reference_text><pubmed_id>10534261</pubmed_id></reference><reference><reference_text>Rating D, Siemes H, Loscher W: Low CSF GABA concentration in children with febrile convulsions, untreated epilepsy, and meningitis. J Neurol. 1983;230(4):217-25.</reference_text><pubmed_id>6198481</pubmed_id></reference><reference><reference_text>Botez MI, Young SN: Effects of anticonvulsant treatment and low levels of folate and thiamine on amine metabolites in cerebrospinal fluid. Brain. 1991 Feb;114 ( Pt 1A):333-48.</reference_text><pubmed_id>1705463</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Czarnecka J, Cieslak M, Michal K: Application of solid phase extraction and high-performance liquid chromatography to qualitative and quantitative analysis of nucleotides and nucleosides in human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Aug 5;822(1-2):85-90.</reference_text><pubmed_id>15993662</pubmed_id></reference><reference><reference_text>Shaywitz BA, Cohen DJ, Bowers MB: Reduced cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in children with epilepsy. Neurology. 1975 Jan;25(1):72-9.</reference_text><pubmed_id>803305</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Romigi A, Bari M, Placidi F, Marciani MG, Malaponti M, Torelli F, Izzi F, Prosperetti C, Zannino S, Corte F, Chiaramonte C, Maccarrone M: Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy. Epilepsia. 2010 May;51(5):768-72. doi: 10.1111/j.1528-1167.2009.02334.x. Epub 2009 Oct 8.</reference_text><pubmed_id>19817812</pubmed_id></reference><reference><reference_text>Hirai K, Seki T: Cerebrospinal fluid somatostatin levels in febrile seizures and epilepsy in children. Neuropeptides. 2000 Feb;34(1):18-24.</reference_text><pubmed_id>10688964</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference></references></disease><disease>Head injury<references><reference><reference_text>Lambert G, Naredi S, Eden E, Rydenhag B, Friberg P: Monoamine metabolism and sympathetic nervous activation following subarachnoid haemorrhage: influence of gender and hydrocephalus. Brain Res Bull. 2002 May;58(1):77-82.</reference_text><pubmed_id>12121816</pubmed_id></reference><reference><reference_text>Bogusiewicz A, Stratton SL, Ellison DA, Mock DM: Biotin accounts for less than half of all biotin and biotin metabolites in the cerebrospinal fluid of children. Am J Clin Nutr. 2008 Nov;88(5):1291-6.</reference_text><pubmed_id>18996865</pubmed_id></reference><reference><reference_text>Sachse KT, Jackson EK, Wisniewski SR, Gillespie DG, Puccio AM, Clark RS, Dixon CE, Kochanek PM: Increases in cerebrospinal fluid caffeine concentration are associated with favorable outcome after severe traumatic brain injury in humans. J Cereb Blood Flow Metab. 2008 Feb;28(2):395-401. Epub 2007 Aug 8.</reference_text><pubmed_id>17684518</pubmed_id></reference><reference><reference_text>Darwish RS, Amiridze N, Aarabi B: Nitrotyrosine as an oxidative stress marker: evidence for involvement in neurologic outcome in human traumatic brain injury. J Trauma. 2007 Aug;63(2):439-42.</reference_text><pubmed_id>17693848</pubmed_id></reference><reference><reference_text>Bayir H, Kochanek PM, Liu SX, Arroyo A, Osipov A, Jiang J, Wisniewski S, Adelson PD, Graham SH, Kagan VE: Increased S-nitrosothiols and S-nitrosoalbumin in cerebrospinal fluid after severe traumatic brain injury in infants and children: indirect association with intracranial pressure. J Cereb Blood Flow Metab. 2003 Jan;23(1):51-61.</reference_text><pubmed_id>12500091</pubmed_id></reference><reference><reference_text>Burke EJ, Mehlhorn U, Allen SJ: Hyaluronan in cerebrospinal fluid after head injury. Acta Neurol (Napoli). 1994 Jun;16(3):103-9.</reference_text><pubmed_id>7992658</pubmed_id></reference></references></disease><disease>Motor neuron disease<references><reference><reference_text>Shukla R, Rajani M, Barthwal MK, Srivastava N, Dikshit M: Cerebrospinal fluid nitrite and malondialdehyde levels in patients with motor neuron disease. Int J Neurosci. 2003 Aug;113(8):1043-54.</reference_text><pubmed_id>12888419</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Seckl JR, Lightman SL, Guiloff RJ: Elevated cerebrospinal fluid vasopressin in motor neuron disease. J Neurol Neurosurg Psychiatry. 1987 Jun;50(6):795-7.</reference_text><pubmed_id>3612158</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Eosinophilic esophagitis<references><reference><reference_text>Mordechai, Hien, and David S. Wishart</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Acute Lymphoblastic Leukemia<references><reference><reference_text>Bogusiewicz A, Stratton SL, Ellison DA, Mock DM: Biotin accounts for less than half of all biotin and biotin metabolites in the cerebrospinal fluid of children. Am J Clin Nutr. 2008 Nov;88(5):1291-6.</reference_text><pubmed_id>18996865</pubmed_id></reference></references></disease><disease>Dementia<references><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Redjems-Bennani N, Jeandel C, Lefebvre E, Blain H, Vidailhet M, Gueant JL: Abnormal substrate levels that depend upon mitochondrial function in cerebrospinal fluid from Alzheimer patients. Gerontology. 1998;44(5):300-4.</reference_text><pubmed_id>9693263</pubmed_id></reference><reference><reference_text>Jeitner TM, Bogdanov MB, Matson WR, Daikhin Y, Yudkoff M, Folk JE, Steinman L, Browne SE, Beal MF, Blass JP, Cooper AJ: N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. J Neurochem. 2001 Dec;79(5):1109-12.</reference_text><pubmed_id>11739625</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference></references></disease><disease>Epilepsy<references><reference><reference_text>Rainesalo S, Keranen T, Palmio J, Peltola J, Oja SS, Saransaari P: Plasma and cerebrospinal fluid amino acids in epileptic patients. Neurochem Res. 2004 Jan;29(1):319-24.</reference_text><pubmed_id>14992292</pubmed_id></reference><reference><reference_text>Cady EB, Lorek A, Penrice J, Reynolds EO, Iles RA, Burns SP, Coutts GA, Cowan FM: Detection of propan-1,2-diol in neonatal brain by in vivo proton magnetic resonance spectroscopy. Magn Reson Med. 1994 Dec;32(6):764-7.</reference_text><pubmed_id>7869898</pubmed_id></reference><reference><reference_text>Perosa SR, Porcionatto MA, Cukiert A, Martins JR, Amado D, Nader HB, Cavalheiro EA, Leite JP, Naffah-Mazzacoratti MG: Extracellular matrix components are altered in the hippocampus, cortex, and cerebrospinal fluid of patients with mesial temporal lobe epilepsy. Epilepsia. 2002;43 Suppl 5:159-61.</reference_text><pubmed_id>12121313</pubmed_id></reference><reference><reference_text>Spanaki MV, Siegel H, Kopylev L, Fazilat S, Dean A, Liow K, Ben-Menachem E, Gaillard WD, Theodore WH: The effect of vigabatrin (gamma-vinyl GABA) on cerebral blood flow and metabolism. Neurology. 1999 Oct 22;53(7):1518-22.</reference_text><pubmed_id>10534261</pubmed_id></reference><reference><reference_text>Rating D, Siemes H, Loscher W: Low CSF GABA concentration in children with febrile convulsions, untreated epilepsy, and meningitis. J Neurol. 1983;230(4):217-25.</reference_text><pubmed_id>6198481</pubmed_id></reference><reference><reference_text>Botez MI, Young SN: Effects of anticonvulsant treatment and low levels of folate and thiamine on amine metabolites in cerebrospinal fluid. Brain. 1991 Feb;114 ( Pt 1A):333-48.</reference_text><pubmed_id>1705463</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Czarnecka J, Cieslak M, Michal K: Application of solid phase extraction and high-performance liquid chromatography to qualitative and quantitative analysis of nucleotides and nucleosides in human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Aug 5;822(1-2):85-90.</reference_text><pubmed_id>15993662</pubmed_id></reference><reference><reference_text>Shaywitz BA, Cohen DJ, Bowers MB: Reduced cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in children with epilepsy. Neurology. 1975 Jan;25(1):72-9.</reference_text><pubmed_id>803305</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Romigi A, Bari M, Placidi F, Marciani MG, Malaponti M, Torelli F, Izzi F, Prosperetti C, Zannino S, Corte F, Chiaramonte C, Maccarrone M: Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy. Epilepsia. 2010 May;51(5):768-72. doi: 10.1111/j.1528-1167.2009.02334.x. Epub 2009 Oct 8.</reference_text><pubmed_id>19817812</pubmed_id></reference><reference><reference_text>Hirai K, Seki T: Cerebrospinal fluid somatostatin levels in febrile seizures and epilepsy in children. Neuropeptides. 2000 Feb;34(1):18-24.</reference_text><pubmed_id>10688964</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference></references></disease><disease>Head injury<references><reference><reference_text>Lambert G, Naredi S, Eden E, Rydenhag B, Friberg P: Monoamine metabolism and sympathetic nervous activation following subarachnoid haemorrhage: influence of gender and hydrocephalus. Brain Res Bull. 2002 May;58(1):77-82.</reference_text><pubmed_id>12121816</pubmed_id></reference><reference><reference_text>Bogusiewicz A, Stratton SL, Ellison DA, Mock DM: Biotin accounts for less than half of all biotin and biotin metabolites in the cerebrospinal fluid of children. Am J Clin Nutr. 2008 Nov;88(5):1291-6.</reference_text><pubmed_id>18996865</pubmed_id></reference><reference><reference_text>Sachse KT, Jackson EK, Wisniewski SR, Gillespie DG, Puccio AM, Clark RS, Dixon CE, Kochanek PM: Increases in cerebrospinal fluid caffeine concentration are associated with favorable outcome after severe traumatic brain injury in humans. J Cereb Blood Flow Metab. 2008 Feb;28(2):395-401. Epub 2007 Aug 8.</reference_text><pubmed_id>17684518</pubmed_id></reference><reference><reference_text>Darwish RS, Amiridze N, Aarabi B: Nitrotyrosine as an oxidative stress marker: evidence for involvement in neurologic outcome in human traumatic brain injury. J Trauma. 2007 Aug;63(2):439-42.</reference_text><pubmed_id>17693848</pubmed_id></reference><reference><reference_text>Bayir H, Kochanek PM, Liu SX, Arroyo A, Osipov A, Jiang J, Wisniewski S, Adelson PD, Graham SH, Kagan VE: Increased S-nitrosothiols and S-nitrosoalbumin in cerebrospinal fluid after severe traumatic brain injury in infants and children: indirect association with intracranial pressure. J Cereb Blood Flow Metab. 2003 Jan;23(1):51-61.</reference_text><pubmed_id>12500091</pubmed_id></reference><reference><reference_text>Burke EJ, Mehlhorn U, Allen SJ: Hyaluronan in cerebrospinal fluid after head injury. Acta Neurol (Napoli). 1994 Jun;16(3):103-9.</reference_text><pubmed_id>7992658</pubmed_id></reference></references></disease><disease>Motor neuron disease<references><reference><reference_text>Shukla R, Rajani M, Barthwal MK, Srivastava N, Dikshit M: Cerebrospinal fluid nitrite and malondialdehyde levels in patients with motor neuron disease. Int J Neurosci. 2003 Aug;113(8):1043-54.</reference_text><pubmed_id>12888419</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Seckl JR, Lightman SL, Guiloff RJ: Elevated cerebrospinal fluid vasopressin in motor neuron disease. J Neurol Neurosurg Psychiatry. 1987 Jun;50(6):795-7.</reference_text><pubmed_id>3612158</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Eosinophilic esophagitis<references><reference><reference_text>Mordechai, Hien, and David S. Wishart</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease><disease>Acute Lymphoblastic Leukemia<references><reference><reference_text>Bogusiewicz A, Stratton SL, Ellison DA, Mock DM: Biotin accounts for less than half of all biotin and biotin metabolites in the cerebrospinal fluid of children. Am J Clin Nutr. 2008 Nov;88(5):1291-6.</reference_text><pubmed_id>18996865</pubmed_id></reference></references></disease><disease>Dementia<references><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Redjems-Bennani N, Jeandel C, Lefebvre E, Blain H, Vidailhet M, Gueant JL: Abnormal substrate levels that depend upon mitochondrial function in cerebrospinal fluid from Alzheimer patients. Gerontology. 1998;44(5):300-4.</reference_text><pubmed_id>9693263</pubmed_id></reference><reference><reference_text>Jeitner TM, Bogdanov MB, Matson WR, Daikhin Y, Yudkoff M, Folk JE, Steinman L, Browne SE, Beal MF, Blass JP, Cooper AJ: N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. J Neurochem. 2001 Dec;79(5):1109-12.</reference_text><pubmed_id>11739625</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference></references></disease><disease>Epilepsy<references><reference><reference_text>Rainesalo S, Keranen T, Palmio J, Peltola J, Oja SS, Saransaari P: Plasma and cerebrospinal fluid amino acids in epileptic patients. Neurochem Res. 2004 Jan;29(1):319-24.</reference_text><pubmed_id>14992292</pubmed_id></reference><reference><reference_text>Cady EB, Lorek A, Penrice J, Reynolds EO, Iles RA, Burns SP, Coutts GA, Cowan FM: Detection of propan-1,2-diol in neonatal brain by in vivo proton magnetic resonance spectroscopy. Magn Reson Med. 1994 Dec;32(6):764-7.</reference_text><pubmed_id>7869898</pubmed_id></reference><reference><reference_text>Perosa SR, Porcionatto MA, Cukiert A, Martins JR, Amado D, Nader HB, Cavalheiro EA, Leite JP, Naffah-Mazzacoratti MG: Extracellular matrix components are altered in the hippocampus, cortex, and cerebrospinal fluid of patients with mesial temporal lobe epilepsy. Epilepsia. 2002;43 Suppl 5:159-61.</reference_text><pubmed_id>12121313</pubmed_id></reference><reference><reference_text>Spanaki MV, Siegel H, Kopylev L, Fazilat S, Dean A, Liow K, Ben-Menachem E, Gaillard WD, Theodore WH: The effect of vigabatrin (gamma-vinyl GABA) on cerebral blood flow and metabolism. Neurology. 1999 Oct 22;53(7):1518-22.</reference_text><pubmed_id>10534261</pubmed_id></reference><reference><reference_text>Rating D, Siemes H, Loscher W: Low CSF GABA concentration in children with febrile convulsions, untreated epilepsy, and meningitis. J Neurol. 1983;230(4):217-25.</reference_text><pubmed_id>6198481</pubmed_id></reference><reference><reference_text>Botez MI, Young SN: Effects of anticonvulsant treatment and low levels of folate and thiamine on amine metabolites in cerebrospinal fluid. Brain. 1991 Feb;114 ( Pt 1A):333-48.</reference_text><pubmed_id>1705463</pubmed_id></reference><reference><reference_text>Kobayashi K, Koide Y, Yoshino K, Shohmori T: [P-hydroxyphenylacetic acid concentrations in cerebrospinal fluid]. No To Shinkei. 1982 Aug;34(8):769-74.</reference_text><pubmed_id>7126379</pubmed_id></reference><reference><reference_text>Czarnecka J, Cieslak M, Michal K: Application of solid phase extraction and high-performance liquid chromatography to qualitative and quantitative analysis of nucleotides and nucleosides in human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Aug 5;822(1-2):85-90.</reference_text><pubmed_id>15993662</pubmed_id></reference><reference><reference_text>Shaywitz BA, Cohen DJ, Bowers MB: Reduced cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in children with epilepsy. Neurology. 1975 Jan;25(1):72-9.</reference_text><pubmed_id>803305</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Romigi A, Bari M, Placidi F, Marciani MG, Malaponti M, Torelli F, Izzi F, Prosperetti C, Zannino S, Corte F, Chiaramonte C, Maccarrone M: Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy. Epilepsia. 2010 May;51(5):768-72. doi: 10.1111/j.1528-1167.2009.02334.x. Epub 2009 Oct 8.</reference_text><pubmed_id>19817812</pubmed_id></reference><reference><reference_text>Hirai K, Seki T: Cerebrospinal fluid somatostatin levels in febrile seizures and epilepsy in children. Neuropeptides. 2000 Feb;34(1):18-24.</reference_text><pubmed_id>10688964</pubmed_id></reference><reference><reference_text>Peters JG: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. Eur Neurol. 1979;18(1):15-8.</reference_text><pubmed_id>436860</pubmed_id></reference></references></disease><disease>Head injury<references><reference><reference_text>Lambert G, Naredi S, Eden E, Rydenhag B, Friberg P: Monoamine metabolism and sympathetic nervous activation following subarachnoid haemorrhage: influence of gender and hydrocephalus. Brain Res Bull. 2002 May;58(1):77-82.</reference_text><pubmed_id>12121816</pubmed_id></reference><reference><reference_text>Bogusiewicz A, Stratton SL, Ellison DA, Mock DM: Biotin accounts for less than half of all biotin and biotin metabolites in the cerebrospinal fluid of children. Am J Clin Nutr. 2008 Nov;88(5):1291-6.</reference_text><pubmed_id>18996865</pubmed_id></reference><reference><reference_text>Sachse KT, Jackson EK, Wisniewski SR, Gillespie DG, Puccio AM, Clark RS, Dixon CE, Kochanek PM: Increases in cerebrospinal fluid caffeine concentration are associated with favorable outcome after severe traumatic brain injury in humans. J Cereb Blood Flow Metab. 2008 Feb;28(2):395-401. Epub 2007 Aug 8.</reference_text><pubmed_id>17684518</pubmed_id></reference><reference><reference_text>Darwish RS, Amiridze N, Aarabi B: Nitrotyrosine as an oxidative stress marker: evidence for involvement in neurologic outcome in human traumatic brain injury. J Trauma. 2007 Aug;63(2):439-42.</reference_text><pubmed_id>17693848</pubmed_id></reference><reference><reference_text>Bayir H, Kochanek PM, Liu SX, Arroyo A, Osipov A, Jiang J, Wisniewski S, Adelson PD, Graham SH, Kagan VE: Increased S-nitrosothiols and S-nitrosoalbumin in cerebrospinal fluid after severe traumatic brain injury in infants and children: indirect association with intracranial pressure. J Cereb Blood Flow Metab. 2003 Jan;23(1):51-61.</reference_text><pubmed_id>12500091</pubmed_id></reference><reference><reference_text>Burke EJ, Mehlhorn U, Allen SJ: Hyaluronan in cerebrospinal fluid after head injury. Acta Neurol (Napoli). 1994 Jun;16(3):103-9.</reference_text><pubmed_id>7992658</pubmed_id></reference></references></disease><disease>Motor neuron disease<references><reference><reference_text>Shukla R, Rajani M, Barthwal MK, Srivastava N, Dikshit M: Cerebrospinal fluid nitrite and malondialdehyde levels in patients with motor neuron disease. Int J Neurosci. 2003 Aug;113(8):1043-54.</reference_text><pubmed_id>12888419</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Seckl JR, Lightman SL, Guiloff RJ: Elevated cerebrospinal fluid vasopressin in motor neuron disease. J Neurol Neurosurg Psychiatry. 1987 Jun;50(6):795-7.</reference_text><pubmed_id>3612158</pubmed_id></reference></references></disease><disease>Multiple sclerosis<references><reference><reference_text>Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J, Cozzone PJ: Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007 Jul 4;2(7):e595.</reference_text><pubmed_id>17611627</pubmed_id></reference><reference><reference_text>Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I: Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med. 2004 Feb;42(2):186-91.</reference_text><pubmed_id>15061359</pubmed_id></reference><reference><reference_text>Leoni V, Lutjohann D, Masterman T: Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res. 2005 Feb;46(2):191-5. Epub 2004 Dec 1.</reference_text><pubmed_id>15576852</pubmed_id></reference><reference><reference_text>Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM: Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003 Sep;28(9):1321-8.</reference_text><pubmed_id>12938853</pubmed_id></reference><reference><reference_text>Shaw CE, Dunbar PR, Macaulay HA, Neale TJ: Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol. 1995 Jan;242(2):53-8.</reference_text><pubmed_id>7707089</pubmed_id></reference><reference><reference_text>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W: Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007 Jun;53(6):1129-36. Epub 2007 Mar 23.</reference_text><pubmed_id>17384003</pubmed_id></reference><reference><reference_text>Syburra C, Passi S: Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh (1999). 1999 May-Jun;71(3):112-5.</reference_text><pubmed_id>10609336</pubmed_id></reference><reference><reference_text>Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6.</reference_text><pubmed_id>16244395</pubmed_id></reference><reference><reference_text>Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002 May;9(3):221-6.</reference_text><pubmed_id>11985629</pubmed_id></reference><reference><reference_text>Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, Papageorgiou C: Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand. 1999 Jun;99(6):387-92.</reference_text><pubmed_id>10577274</pubmed_id></reference><reference><reference_text>Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E: Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 2010 May 28;1333:64-71. doi: 10.1016/j.brainres.2010.03.073. Epub 2010 Mar 27.</reference_text><pubmed_id>20347721</pubmed_id></reference><reference><reference_text>Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J: CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci. 2010 Aug 15;295(1-2):41-5. doi: 10.1016/j.jns.2010.05.014. Epub 2010 Jun 11.</reference_text><pubmed_id>20541774</pubmed_id></reference><reference><reference_text>Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010 Apr;120(4):301-4. doi: 10.3109/00207451003695690.</reference_text><pubmed_id>20374079</pubmed_id></reference><reference><reference_text>Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K, Horiuchi M, Miki T, Kira JI: Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008 May;14(4):557-60. doi: 10.1177/1352458507085760.</reference_text><pubmed_id>18562510</pubmed_id></reference><reference><reference_text>Visconti A, Cotichini R, Cannoni S, Bocca B, Forte G, Ghazaryan A, Santucci S, D'Ippolito C, Stazi MA, Salvetti M, Alimonti A, Ristori G: Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study. Ann Ist Super Sanita. 2005;41(2):217-22.</reference_text><pubmed_id>16244396</pubmed_id></reference></references></disease><disease>Colorectal cancer<references><reference><reference_text>Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.</reference_text><pubmed_id>7482520</pubmed_id></reference><reference><reference_text>Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.</reference_text><pubmed_id>19006102</pubmed_id></reference><reference><reference_text>Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.</reference_text><pubmed_id>23940645</pubmed_id></reference><reference><reference_text>Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.</reference_text><pubmed_id>24424155</pubmed_id></reference><reference><reference_text>Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.</reference_text><pubmed_id>20156336</pubmed_id></reference><reference><reference_text>Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.</reference_text><pubmed_id>19678709</pubmed_id></reference><reference><reference_text>Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.</reference_text><pubmed_id>22148915</pubmed_id></reference><reference><reference_text>Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.</reference_text><pubmed_id>25105552</pubmed_id></reference><reference><reference_text>Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.</reference_text><pubmed_id>21773981</pubmed_id></reference><reference><reference_text>Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.</reference_text><pubmed_id>25037050</pubmed_id></reference><reference><reference_text>Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.</reference_text><pubmed_id>27015276</pubmed_id></reference><reference><reference_text>Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.</reference_text><pubmed_id>27107423</pubmed_id></reference><reference><reference_text>Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.</reference_text><pubmed_id>27275383</pubmed_id></reference><reference><reference_text>Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.</reference_text><pubmed_id>28587349</pubmed_id></reference><reference><reference_text>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</reference_text><pubmed_id>28587349</pubmed_id></reference></references></disease><disease>Eosinophilic esophagitis<references><reference><reference_text>Mordechai, Hien, and David S. Wishart</reference_text><pubmed_id>nan</pubmed_id></reference></references></disease></diseases></range></ranges></Metabolites>